ZooPharm
ZooPharm is a Wyoming-based veterinary compounding pharmacy that formulates patented anesthesia and pain-management medications — including the BAM™ Kit and slow-release buprenorphine — for wildlife, zoo, exotic species, and companion animals, operating under 50-state pharmacy licensure and owned by Wedgewood Pharmacy since 2020.
- Company typePrivate
- Founded-
- HeadquartersLaramie, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ZooPharm does
ZooPharm is a veterinary compounding pharmacy headquartered in Laramie, Wyoming, that formulates and dispenses specialized anesthesia and pain-management medications for non-domestic species, resident wildlife, captive exotic breeds, and companion animals. The company was a wholly owned subsidiary of Wildlife Pharmaceuticals, Inc. (Windsor, Colorado), founded by Dr. Bill Lance, and was acquired by Wedgewood Pharmacy in May 2020, with the ZooPharm brand maintained post-closing. The product portfolio is anchored by two patented formulations: the BAM™ Kit — a combination of Butorphanol tartrate, Azaperone tartrate, and Medetomidine hydrochloride plus a reversal agent used to immobilize a broad range of wildlife and zoo species — and a slow-release buprenorphine prescribed primarily for companion-animal post-operative recovery. ZooPharm also supplies sustained-release analgesics and anesthetics for wildlife and zoo pain management.
The business operates a prescription-based revenue model, distributing compounded preparations directly to veterinary practices serving the wildlife and zoo market segment. ZooPharm holds pharmacy licensure in all 50 U.S. states, giving it near-universal domestic distribution reach for a specialist catalog. Its differentiation rests on a combination of patented drug formulations, 50-state regulatory footprint, and exclusive domain focus on species for which commercially manufactured medications are typically unavailable. The customer base is a long tail of wildlife veterinarians, accredited zoos, and exotic-animal practices; no enterprise anchor customers are disclosed.
Following the 2020 acquisition by Wedgewood Pharmacy — the largest U.S. animal-health compounding pharmacy, majority-owned by New Harbor Capital since 2016 — ZooPharm gained access to Wedgewood's formulary and 50,000+ veterinary prescribers, while contributing its specialty preparations to Wedgewood's broader customer base. The combined entity also created Wedgewood Connect, a 503B outsourcing facility for sterile injectables and ophthalmics, signaling adjacent expansion of the platform relevant to ZooPharm's specialist needs. ZooPharm's website (wildpharm.com) and full integration into Wedgewood's operations make its post-acquisition financials not separately disclosed.
ZooPharm firmographics
Firmographics- Name
- ZooPharm
- Legal name
- ZooPharm
- Website
- https://wildpharm.com
- Company type
- Private
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- ZooPharm is a Wyoming-based veterinary compounding pharmacy that formulates patented anesthesia and pain-management medications — including the BAM™ Kit and slow-release buprenorphine — for wildlife, zoo, exotic species, and companion animals, operating under 50-state pharmacy licensure and owned by Wedgewood Pharmacy since 2020.
- Ownership category
- akta.pro rank
Where ZooPharm is headquartered
LocationHeadquarters
- HQ city
- Laramie
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ZooPharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure
Revenue model
- Veterinary Compounding Medications: Compounded medications customized to the unique needs of animal patients, particularly non-domestic species, wildlife, and zoo animals. Medications are prepared by specially trained pharmacists under strict standards.
Go-to-market motion1 record
Distribution channels1 record
ZooPharm product offering
Product offeringCore offering
ZooPharm is a veterinary compounding pharmacy that prepares specialized anesthesia and pain-management medications for non-domestic species, resident wildlife, captive exotic breeds, and companion animals. Its portfolio includes the patented BAM™ Kit for immobilizing a broad range of species, a patented slow-release buprenorphine for post-operative recovery, and sustained-release analgesics and anesthetics.
Product overview
ZooPharm is a veterinary compounding pharmacy that provides specialized veterinary-anesthesia and pain-management medications. The company operates as part of Wildlife Pharmaceuticals, Inc. and serves veterinarians and patients in the wildlife and zoo markets. Its product portfolio includes the patented BAM™ Kit (for immobilization of non-domestic species), patented slow-release buprenorphine (for companion animal post-operative recovery), and sustained-release analgesics and anesthetics for pain management. The company is licensed in all 50 states. Following acquisition by Wedgewood Pharmacy, the ZooPharm brand will be maintained while Wedgewood's animal health formulary becomes available to ZooPharm's client base.
Differentiator
Problem solved
Functional benefit
Products and services
- BAM™ Kit A patented drug combination (Butorphanol tartrate, Azaperone tartrate, and Medetomidine hydrochloride) plus a reversal agent used to immobilize a broad range of wildlife, zoo, and non-domestic species during veterinary procedures.
- Slow Release Buprenorphine A patented, slow-release buprenorphine formulation prescribed primarily to companion animals for post-operative recovery and pain management.
- Sustained-Release Analgesics and Anesthetics Sustained-release pain management medications used to manage pain in wildlife, zoo species, captive exotic breeds, and companion animals.
Companies that use ZooPharm
Customer profileSegments1 record
Ideal customer profiles2 records
ZooPharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
ZooPharm partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Wedgewood PharmacycoreWedgewood Pharmacy has agreed to acquire Wildlife Pharmaceuticals, Inc., Windsor, Colorado, and its wholly owned pharmacy subsidiary, ZooPharm, Laramie, Wyoming. The transaction was expected to close within 90 days, pending regulatory approvals. Wedgewood Pharmacy intends to maintain the ZooPharm brand while making Wedgewood Pharmacy's extensive animal health formulary available to ZooPharm's client base. ZooPharm's specialized preparations also will be offered to Wedgewood Pharmacy's veterinary customers.
Scale indicators1 record
Recent moves5 records
Expansion highlights4 records
ZooPharm competitors and assessment
Company assessmentOthers
- Medisca: Global supplier of pharmaceutical compounding ingredients, equipment, and bases to compounding pharmacies including 503A and 503B facilities. Adjacent ecosystem participant enabling compounding pharmacies like ZooPharm to source APIs and excipients.
Direct peers
- Stokes Pharmacy: Veterinary compounding pharmacy serving companion animal, equine, and exotics markets with customized formulations. Comparable business model (state-regulated compounding for animal health) and overlapping prescriber base with ZooPharm.
- Diamondback Drugs: Animal-health compounding pharmacy acquired by Wedgewood in July 2018, headquartered in Scottsdale, Arizona. Direct comparable: a veterinary compounding pharmacy serving companion animal and equine prescribers, now operating alongside ZooPharm within the Wedgewood portfolio.
- Wedgewood Pharmacy: Acquirer of ZooPharm in 2020 and the largest animal health compounding pharmacy in the U.S. Operates state-licensed compounding facilities serving 50,000+ prescribers with a broad veterinary and human health formulary; directly comparable business model (compounding pharmacy for animal health) and now distributes ZooPharm's specialty formulations.
- Wildlife Pharmaceuticals, Inc. Former parent company of ZooPharm (Windsor, Colorado). Direct peer as the originating entity behind the BAM Kit and slow-release buprenorphine formulations, with overlapping portfolio in wildlife pharmaceuticals.
- Apothecary by Elixin (formerly Avrio Pharmacy): Compounding pharmacy serving both human and veterinary markets including exotic and zoo species. Direct comparable on compounding model and exotic-animal customer overlap.
- Letco Medical (Letco Companies): Veterinary compounding supply company providing APIs, bases, and equipment to compounding pharmacists serving veterinary practices. Comparable in the veterinary compounding ecosystem; while not a dispenser, it serves the same customer base of vet compounders.
- Wedgewood Connect (formerly Leiters Enterprises 503B facility): Wedgewood's 503B outsourcing facility in San Jose, California, acquired in 2020 alongside ZooPharm. Direct comparable as a sibling compounding operation within the same Wedgewood umbrella, but operating under FDA cGMP standards rather than state-only regulation.
Broad incumbents
- Elanco Animal Health: Major animal health pharmaceutical company offering a full portfolio of therapeutics, including pain management and companion animal products. Broad incumbent with overlap in the pain/anesthesia therapeutic category ZooPharm addresses.
- Zoetis: Largest global animal health pharmaceutical company offering vaccines, parasiticides, and pharmaceuticals across companion and livestock species. Broader incumbent whose commercial portfolio competes adjacent to ZooPharm's pain-management and anesthesia franchise.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
ZooPharm social profiles
Digital presenceZooPharm compliance and trust
Trust signalCompliance1 record
ZooPharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
ZooPharm leadership team
Management profileNumber of profiles
ZooPharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ZooPharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ZooPharm
What does ZooPharm do?
ZooPharm is a veterinary compounding pharmacy that prepares specialized anesthesia and pain-management medications for non-domestic species, resident wildlife, captive exotic breeds, and companion animals. Its portfolio includes the patented BAM™ Kit for immobilizing a broad range of species, a patented slow-release buprenorphine for post-operative recovery, and sustained-release analgesics and anesthetics.
Is ZooPharm a public or private company?
ZooPharm is a private company. It is classified as corporate owned and is currently acquired.
When was ZooPharm founded?
ZooPharm was founded in -1. It employs 11 to 50 people.
Where is ZooPharm based?
ZooPharm is headquartered in Laramie, United States, in the North America region.
How does ZooPharm make money?
One revenue line is on record: veterinary Compounding Medications.
Who are ZooPharm's main competitors?
Medisca is listed as an others. Direct peers are Stokes Pharmacy, Diamondback Drugs, Wedgewood Pharmacy, Wildlife Pharmaceuticals, Inc., Apothecary by Elixin (formerly Avrio Pharmacy), Letco Medical (Letco Companies) and Wedgewood Connect (formerly Leiters Enterprises 503B facility). Broad incumbents are Elanco Animal Health and Zoetis.
Does ZooPharm have an API?
No public API is recorded for ZooPharm.